HRV Biofeedback and Vagus Nerve Training

Download this page as PDF · Summary

1. What HRV Biofeedback and Vagus Nerve Training Are

HRV biofeedback is a behavioural therapeutic method in which patients receive real-time feedback on their heart rate variability (HRV) via sensors. The goal is to learn rhythmic breathing to enhance coherence between heartbeat and respiration. The method originates from psychophysiology and is often combined with relaxation techniques. Non-invasive vagus nerve stimulation (nVNS) uses electrical or mechanical stimuli (e.g., via the ear or neck) to activate the vagus nerve. Both approaches aim to modulate the autonomic nervous system, particularly by strengthening the parasympathetic component.

The common denominator of both methods is the measurement of HRV as a key biomarker. HRV describes the temporal fluctuations between successive heartbeats and is considered an indicator of the adaptability of the autonomic nervous system. While HRV biofeedback relies on behavioural change, nVNS acts through direct stimulation. Both approaches are often combined with breathing techniques, meditation, or cognitive training. Implementation varies: HRV biofeedback is typically delivered via mobile devices or laboratory setups, while nVNS uses transcutaneous stimulators. A critical consideration in interpreting studies is that HRV changes do not automatically equate to clinical effects.

2. What the Studies Show in Detail

The pivotal human studies and key reviews—organised by application, including population, duration, preparation, outcome measures, and results—as reported in the original publications. Numbers are included only where explicitly stated in the studies.

Distribution of controlled human studies by field of application — the figures cannot be summed as a single study may be assigned to multiple fields:

Safety and Tolerability

Participants received either nVNS or sham stimulation for up to 1 month. The primary endpoint was the response rate, defined as pain freedom at 15 minutes without rescue medication. In the subgroup with episodic cluster headache (eCH), nVNS showed a significant effect (34.2% vs. sham). In chronic cluster headache (cCH), no difference was observed. The study suggests that nVNS may be safe in eCH, but data on long-term tolerability are lacking 2.

The response rate at 15 minutes was 48% in the nVNS group and 6% in the sham group for eCH (P < 0.01), whereas no difference was observed in cCH (5% vs. 13%). The study provided a hint of an effect of nVNS in eCH but no effect in cCH. The most common adverse effects were local skin irritation and transient pain at the stimulation site. The study highlights the tolerability of nVNS, though data on long-term use are lacking 3.

A multicentre, randomised, double-blind, sham-controlled study (PREMIUM) involving 477 patients investigated nVNS for the preventive treatment of episodic migraine. Participants were instructed to perform two 120-second stimulations three times daily over 12 weeks. The primary endpoint (reduction in monthly migraine days) showed no significant difference between nVNS (2.26 days) and sham (1.80 days, P = 0.15). However, a post-hoc analysis of participants who completed at least 67% of the prescribed stimulations revealed a difference (2.27 vs. 1.53 days, P = 0.043). The study suggests that nVNS could have an effect with good compliance, though data on the optimal stimulation dose and duration are lacking.

Assumption: The available studies indicate that nVNS and HRV biofeedback are generally well tolerated, causing only mild, transient side effects such as local skin irritation or pain at the stimulation site. Safety appears plausible even with prolonged use, though systematic long-term studies are still pending.

Systematic investigations into the long-term tolerability of nVNS and HRV biofeedback, as well as data on rare but potentially serious adverse effects, stand out as areas where further research is needed.

Overall Picture

3. How Robust the Research Is

The controlled human studies examined represent a substantial portion of the evidence base for HRV biofeedback and vagus nerve training, alongside a comparable number of observational studies. Among these studies, depression, cluster headache, and migraine are the most frequently investigated applications, while cognition and fatigue are also common. Inflammation, cardiovascular, and oncology outcomes are far less common within this field. Basic science and mechanism reviews dominate citation frequency, indicating a strong interest in mechanisms of action for these methods. Animal and cell studies play a subordinate role in this research area.

The methodological quality of the studies is heterogeneous. Double-blind, sham-controlled designs are primarily found in nVNS studies (e.g., for cluster headache or migraine), whereas HRV biofeedback is often investigated in open-label or single-blind studies. Cognitive effects and fatigue are frequently measured using subjective scales, which may favour placebo effects and do not constitute evidence of clinical efficacy. Safety data are robust, but long-term studies are lacking. Review articles highlight that while HRV changes are consistently detectable, they do not constitute evidence of clinical efficacy. Combination studies (e.g., with mindfulness or exercise) complicate the isolation of effects.

4. Common Claims—and What the Data Show

5. The Most Robust Studies

Ranked by evidential strength, not by prominence. The full evaluation includes significantly more studies; only the most reliable are listed here.

Controlled Human Studies

• 1 Preliminary results of an open label study of heart rate variability biofeedback for the treatment of major depression (2007)
• 2 Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study (2016)
• 3 Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT (2018)
• Non-invasive vagus nerve stimulation acutely improves spontaneous cardiac baroreflex sensitivity in healthy young men: A randomized placebo-controlled trial (2017)
• 4 Heart rate variability biofeedback as a behavioural neurocardiac intervention to enhance vagal heart rate control (2005)
• Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled trial (2019)
• Short-term transcutaneous non-invasive vagus nerve stimulation may reduce disease activity and pro-inflammatory cytokines in rheumatoid arthritis: Results of a pilot study (2021)
• A randomised controlled trial comparing daily mindfulness meditations, biofeedback exercises, and daily physical exercise on attention control, executive functioning, and mindful awareness (2016)
• 5 Heart rate variability biofeedback based on slow-paced breathing with immersive virtual reality nature scenery (2019)
• 6 Open-label pilot study: Non-invasive vagal nerve stimulation improves symptoms and gastric emptying in patients with idiopathic gastroparesis (2020)
• 7 Combined heart rate variability and pulse oximetry biofeedback for chronic obstructive pulmonary disease: Preliminary findings (2004)
• Non-invasive brain stimulation techniques for the improvement of upper limb motor function and performance in activities of daily living after stroke: A systematic review (2023)
• 8 Non-invasive stimulation of vagal afferents reduces gastric frequency (2020)
• 9 Non-invasive vagus nerve stimulation enhances mood recovery after effort exertion (2022)
• Neurophysiological approach by self-control of the stress-related autonomic nervous system in patients with depression, stress, and anxiety (2021)
• 10 Increasing coordination and responsivity of emotion-related brain regions with a heart rate variability biofeedback randomised controlled trial (2023)
• Inter-ictal assay of peripheral circulating inflammatory mediators in migraine patients under adjunctive cervical non-invasive vagus nerve stimulation (nVNS) (2019)
• Non-invasive vagus nerve stimulation for COVID-19: Results from a randomised controlled trial (SAVIOR I) (2022)
• 11 Effects of heart rate variability biofeedback on EEG alpha asymmetry and anxiety symptoms in male athletes: A pilot study (2016)
• 12 Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts (2020)
• 13 Non-invasive vagus nerve stimulation for migraine: A systematic review and meta-analysis of randomised controlled trials (2023)
• Vagus nerve stimulation in ischaemic stroke: A systematic review (2023)
• 14 Heart rate variability biofeedback for paediatric irritable bowel syndrome and functional abdominal pain: A clinical replication series (2014)
• 15 One-year cardiovascular prognosis of the randomised, controlled, short-term heart rate variability biofeedback trial among patients with coronary artery disease (2018)

6. Summary

1) What is established: HRV biofeedback and nVNS are safe and well-tolerated, with mild, transient side effects such as local skin irritation. In episodic cluster headache, nVNS showed efficacy in double-blind studies (response rate 34–48%), whereas no effects have been shown for the chronic form. For migraine, one study suggests a potential preventive effect with high compliance, though without a significant difference in the primary endpoint. HRV changes are consistently detectable but do not constitute evidence of clinical efficacy. The evidence base is heterogeneous, with methodological limitations such as small sample sizes, lack of blinding, or placebo effects. Safety and mechanisms have been studied more extensively than clinical outcomes.

2) What is plausible and what this might imply (hypothesis): Hypothesis: The methods may exert anti-inflammatory or stress-reducing effects via parasympathetic enhancement, though controlled human trials on this are limited. Hypothesis: HRV biofeedback could serve as a supportive measure in combination with other therapies (e.g., mindfulness) without acting as a standalone causal treatment. Hypothesis: nVNS may represent an option for specific indications (e.g., episodic cluster headache) if long-term data confirm efficacy. Hypothesis: The discrepancy between HRV changes and clinical effects suggests that physiological markers cannot be automatically equated with therapeutic benefit. Combination studies complicate the isolation of specific effects, limiting the interpretation of results.

3) What a study would need to clarify: Systematic long-term studies with follow-up phases of at least 6–12 months are necessary to capture sustained effects and rare side effects. Direct comparisons with established therapies (e.g., medication, behavioural therapy) would better contextualise the clinical relevance of these methods. Studies with sufficient power and rigorous methodological standards (double-blinding, sham control) must determine whether HRV biofeedback or nVNS can be targeted to specific patient groups (e.g., by age, comorbidities). Additionally, the dose-response relationship should be investigated to define optimal stimulation parameters (duration, intensity, frequency). Finally, studies are needed to disentangle mechanisms (e.g., anti-inflammatory effects) from clinical outcomes to clarify the causal role of these interventions.

7. What Remains Unclear

• Dose-response relationship: It remains unclear whether longer or more intensive stimulation in the studied ranges yields better effects—or whether habituation effects occur.
• Long-term effects: Nearly all studies examine short-term effects. Whether HRV biofeedback or nVNS produce sustained benefits is unknown.
• Patient selection: Which patient groups (e.g., by age, pre-existing conditions) benefit most has not been systematically investigated.